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Abstract
Adult mesenchymal stem cells (MSCs) represent a subject of intense experimental and biomedical interest. Recently,
trophic activities of MSCs have become the topic of a number of revealing studies that span both basic and clinical
fields. In this review, we focus on recent investigations that have elucidated trophic mechanisms and shed light on
MSC clinical efficacy relevant to musculoskeletal applications. Innate differences due to MSC sourcing may play a
role in the clinical utility of isolated MSCs. Pain management, osteochondral, nerve, or blood vessel support by
MSCs derived from both autologous and allogeneic sources have been examined. Recent mechanistic insights into
the trophic activities of these cells point to ultimate regulation by nitric oxide, nuclear factor-kB, and indoleamine,
among other signaling pathways. Classic growth factors and cytokines—such as VEGF, CNTF, GDNF, TGF-β,
interleukins (IL-1β, IL-6, and IL-8), and C-C ligands (CCL-2, CCL-5, and CCL-23)—serve as paracrine control molecules
secreted or packaged into extracellular vesicles, or exosomes, by MSCs. Recent studies have also implicated
signaling by microRNAs contained in MSC-derived exosomes. The response of target cells is further regulated by
their microenvironment, involving the extracellular matrix, which may be modified by MSC-produced matrix
metalloproteinases (MMPs) and tissue inhibitor of MMPs. Trophic activities of MSCs, either resident or introduced
exogenously, are thus intricately controlled, and may be further fine-tuned via implant material modifications. MSCs
are actively being investigated for the repair and regeneration of both osteochondral and other musculoskeletal
tissues, such as tendon/ligament and meniscus. Future rational and effective MSC-based musculoskeletal therapies
will benefit from better mechanistic understanding of MSC trophic activities, for example using analytical “-omics”
profiling approaches.
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Background
From a research, medical, and business standpoint, mes-
enchymal stem cell (MSC)-based therapies are fascinating.
Sales for stem cell products (e.g., as a subset of osteobiolo-
gics) were projected to top $600,000,000 by 2015 [1, 2],
and a recent Scopus search for musculoskeletal and stem
cells resulted in over 3000 documents, with more than a
third being reviews. We have limited this review to
highlighting noteworthy findings and concepts concerned
with the understanding of and challenges with MSC mus-
culoskeletal therapies.
MSCs were discovered in the 1960s [3], named in the
early 1990s [4], and purportedly defined by the mid-
2000s [5]. Despite the proposed criteria, the functional
definition within the literature varies widely. MSCs can
be defined by their ability to adhere to tissue culture
plastic, their expression of several cell surface molecular
epitopes—cluster of differentiation CD73, CD90, and
CD105, and others—as well as their lack of several sur-
face markers, including CD45 [6]. Some previously ex-
cluded markers are debated within certain circles, such
as CD34 and CD146 [7–9]. MSCs can be isolated from a
range of tissues, but the most commonly cited sources
are bone marrow (BM), adipose tissue, muscle, bone,
and perinatal tissues (e.g., Wharton’s Jelly, umbilical
vein/cord blood (UV/UCB), and amnion).
While they were originally utilized clinically in hopes
of harnessing their differentiation and proliferation po-
tential, MSCs are increasingly thought to also influence,
in addition to participating in, tissue function [10, 11],
especially within osteochondral spaces [12]. These MSC
influences can range from relatively rare activities that
require cell contact, such as mitochondrial transfer and
cell fusion, to relatively common paracrine MSC actions
through extracellular microvesicles or secreted factors.
MSCs may modulate the immune response, angiogen-
esis, apoptosis, oxidation level, migration, and/or differ-
entiation/stimulation of surrounding cells [13]. Because
of this alternative use of MSCs, Caplan and Sorell [14]
suggested a renaming of MSCs to medicinal signaling cells
to suggest a new era of MSC clinical relevance due to their
immunomodulatory properties. While acknowledging
progress in the other areas mentioned, this work will focus
on the current debates concerning sourcing, MSC alter-
ations of angiogenesis, cell differentiation/stimulation, and
strategies to improve MSC differentiation.
Sourcing
Sourcing of MSCs has become an area of debate due to
well-recognized potential differences in differentiation
abilities and trophic activities of the derived MSCs. Al-
ternatively sourced MSCs may have different differenti-
ation potentials as BM-MSCs, and they may require
additional supplementation to achieve robust or similar
differentiation. However, while relative abundance and
ease of isolation of MSCs may allow their use for suc-
cessful musculoskeletal interventions [15], there are con-
cerns that diminished numbers of MSCs may be present
in BM as patients age or succumb to disease [16]. One
study found that mouse MSCs from four common
sources (BM, adipose tissue, skeletal muscle, and
myocardium) equally supported endothelial cell (EC)
network formation in vitro and blood vessel forma-
tion in vivo [17]. Muscle-derived stem cells (MDSCs)
and satellite cells are thought to contribute to repair
of skeletal muscle and bone [18–20]. Although the
exact mechanisms remain to be elucidated, cartilage
and muscle health has been provocatively linked with
changes in or lack of multipotent cell activity, includ-
ing diseases such as osteoarthritis (OA, cartilage), sarco-
penia (muscle), and related muscle and motor neuron
diseases [21].
In one study attempting to address the most useful
source of MSCs for angiogenesis through a hindlimb
ischemia model, Bortolotti et al. examined adipose-derived
MSCs (AD-MSCs) and BM-MSCs (along with a subpopu-
lation of CD11-depleted BM-MSCs). They found, as have
many others, that MSCs were not incorporated into the
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healing wound but that wounds, particularly those in mus-
cles, healed more rapidly when exposed to BM-MSCs (re-
gardless of MSC sorting) [22]. Classic proangiogenic,
chemotactic, and remodeling molecules were identified as
being expressed by MSCs, with several factors appearing
prominently in the also effective conditioned medium
(CM) (platelet-derived growth factor-B (PDGFB), trans-
forming growth factor beta (TGF-β), stromal-derived
factor-1 (SDF1), angiopoietin-1 (Ang1), regulator of G-
protein signaling-5 (Rgs5), matrix metalloproteinase-9
(MMP-9), chemokine (C-X-C) ligand-10 (CXCL10), che-
mokine (C-C) ligand (CCL5)) [22].
Work with 5–6-week-old human embryonic BM-
MSCs and MDSCs suggests that MSCs have innate pro-
pensities for adipogenic and myogenic differentiation, re-
spectively, which ultimately affects the organization of
the engineered tissues [16, 23]. MSCs sourced from
older tissue might overcome these propensities depend-
ing on the implantation culture environment [24]. Tak-
ing a cue from the successful use of stem cells from
birth-associated tissues [25], one group recently investi-
gated the angiogenic activity of endometrium/men-
strual blood-sourced multipotent cells, showing that
they support the recruitment of ECs, blood vessels,
and, potentially, the proliferation of hematopoietic stem
cells [26].
An encouraging finding is that the number of MSCs
required to exert trophic action may be far less than ori-
ginally calculated as necessary for tissue replacement,
because a prospective study of BM-MSC vs mixed BM-
MSC + lipoaspirate therapy for OA found no difference
in patient-reported outcomes between the two groups
[27]. Interestingly, increasing body mass index (BMI)
appeared to correlate with patient-reported improve-
ment of function, a link that should be explored in the
future [28].
MSC musculoskeletal clinical use
Evidence for an altered view of MSC efficacy follows re-
sults from clinical trials, several of which have recently
begun to yield data about long-term MSC efficacy in dis-
ease treatment. A large area of MSC-based musculoskel-
etal research has been directed towards the degenerative
joint disease OA, which currently affects approximately
20 million Americans and is projected to affect 20 % of
American adults by 2030 [29]. OA is characterized by
the degeneration of articular cartilage and synovial in-
flammation, which alters associated soft tissue and sub-
chondral bone, resulting in bony lesion and osteophyte
formation. These degenerative events cause pain and
loss of joint mobility and function. Because cartilage has
a lower regenerative capacity than other, more vascular-
ized tissues in the body, arthritis and joint degeneration
are growing targets of MSC-based therapies.
Recent investigations into MSC treatment of OA have
begun to include formal, controlled clinical trials [30] in
addition to many uncontrolled trials by private entities.
Several international companies, including Cartistem,
Regenexx, Regeneus, BioHeart, and Mesoblast, are carry-
ing out phase I and II clinical trials for the treatment of
degenerative joint diseases with allogeneic or autologous,
multipotent cell types that are capable of mesenchymal
differentiation, usually derived from BM or adipose ori-
gin [15, 31, 32]. Several other companies have chosen to
facilitate MSC isolation within the clinic by constructing
machines that quickly sort stem cells from the mixed
populations present in surgically isolated tissue [33]. Al-
though published data have been relatively scarce for
completed trials, adverse events such as tumors, infec-
tions, or premature trial closures have rarely been re-
ported, suggesting safety of MSC-based therapies [34, 35].
The majority of reviewed studies utilize either dissociated
cells injected into the joint space or cells delivered via
seeding in various biocompatible and/or biodegradable
materials.
A recent review details results of nine OA articular
cartilage (knee) clinical trials which utilized cultured
BM-MSCs, noncultured BM concentrate, peripheral
blood-derived stem cells, or cells from the adipose stro-
mal vascular fraction [36]. Some cells were immobilized
with hyaluronan, collagen, platelet gel, and/or fibrin
glue. Others were injected into the joint or at a defect
using only saline. Regardless of cell origin, intra-articular
injection of cells (vs hydrogel or flap immobilization
through open surgery) resulted in improved clinical
function over untreated controls in some studies as long
as 5 years post treatment [36]. Pain relief with minor
return of function was noted in most studies.
Noting the ameliorative effect of MSCs on joint pain,
chronic lower back pain has recently become a target of
MSC therapy. Autologous, scaffold-less BM-MSC injec-
tion into patients with spinal cord injury in a Brazilian
clinical trial suggested clinically meaningful pain relief
and possible improvement in cartilage structure after
6 months and as long as 2 years post treatment, although
the high number of MSCs utilized coupled with the high
cost of the procedure were identified as potential areas for
improvement [37]. In a Spanish study, 7 of 12 patients
showed mild return of function after 6 months when en-
rolled in a phase I safety and efficacy study for BM-MSC
injection for long-term (>6 months) spinal cord injury
[38]; although positive in terms of apparent MSC effect,
the study faced almost immediate criticism from other
researchers due to the small sample size and lack of
appropriate controls [39]. A study by Mesoblast reported
decreased lower back pain in 48 % of allogeneic BM-
MSC-treated patients vs 13 % in placebo controls up to
2 years post injection [40].
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A portion of these analgesic effects could be due to
the anti-inflammatory activity of MSCs. Evidence that a
decrease in granulocyte macrophage colony-stimulating
factor (GM-CSF) resulted from MSC treatment and may
decrease disease severity after 4 months comes from a
rheumatoid arthritis (RA) clinical trial that used MOR103
antibodies to deplete serum GM-CSF [41]. In an excellent
and very recent review of MSC applications to RA, De
Bari described how immunomodulation could play a role
in RA-specific joint degeneration. Immunoregulators,
including interferon gamma (IFN-γ) and tumor necrosis
factor alpha (TNF-α), which are regulated through indo-
leamine 2,3-dioxygenase (IDO) or nitric oxide (NO), and
MSC effects on forkhead box p3+ (Foxp3+) Tregs or CD4+
Th17 cells have been suggested [42]. Interestingly, the
“transformation hypothesis” proposes that MSCs may be-
come transformed by interplay with chronic inflammatory
processes in the joint, resulting in a more aggressive cell
type with abilities to either invade the articular cartilage
and/or circulate, spreading arthritis to unaffected joints
[43, 44]. UV-MSCs may help to relieve the severity of RA
symptoms when combined with disease-modifying anti-
rheumatic treatments [45].
Recent exploration of immunomodulation showed that
AD-MSC surface-bound glycoprotein A repetitions predo-
main/leucine-rich repeat containing-32 (GARP/LRRC32),
found on CD4+/Foxp3+ Tregs, megakaryocytes, and plate-
lets, binds to membrane-bound TGF-β1, holding it in an
inactivated but readily-accessible state. GARP silencing re-
sults in increased secretion and activation of TGF-β1 and
impaired proliferation of AD-MSC as well as activation of
T cells [46]. Immunosuppressive effects of membrane-
bound TGF-β1, especially when bound to extracellular
vesicles (EVs), have also been reported for other MSC
types [47–49].
Mechanisms of MSC trophic activity
Insight into the mechanisms of MSC trophic activity is
advancing across multiple fields (Table 1). Within the
joint space, the MSC secretome is thought to influence
the anabolic tendencies of chondrocytes, chondrocyte
progenitor cells (CPCs), cartilage-derived stem/pro-
genitor cells (CSPCs), synovium-resident multipotent
progenitor cells, osteoblasts/osteoclasts/resident MSCs
within the subchondral bone (especially after microfrac-
ture), and chondrogenic cells within the infrapatellar fat
pad [36, 50, 51]. The MSC secretome can be modified
through permanent or temporary alterations. Several stud-
ies have found that the exposure of MSCs to proinflam-
matory factors, sometimes for as little as a few hours, can
alter the gene and protein expression of MSCs for days
afterwards [52]. Factors known to be secreted or bound to
MSC membranes with anti-inflammatory activities (acti-
vation of Tregs/tolerogenic dendritic cell phenotype; pro-
resolving/M2 macrophage activation; inhibition or proa-
poptosis of T cells, B cells, NK cells, or dendritic cells;
decreasing cytokine production) include: purines, bone
morphogenetic proteins (BMPs, specifically BMP-4),
CD274, CCL2, Connexin 43, cyclooxygenase (COX)/pros-
taglandin (PG), CD95/CD95 ligand, galectins, heme
oxygenase-1, human leukocyte antigen-G (HLA-G), IDO/
kynurenine, interleukin-6 (IL-6), leukemia inhibitory fac-
tor (LIF), NO, TGF-β, tumor necrosis factor-inducible
gene-6 (TSG6), and vascular endothelial growth factor
(VEGF) [53].
In addition to some of the classic chemotactic growth
factors and molecules already mentioned (HGF, PDGF,
and bFGF), MSCs are strongly influenced by the binding
of CXCL12 (SDF1) to CXCR4 [54]. Embryonic muscle
growth and adult muscle repair are thought to be heavily
influenced by MMP-10-regulated CXCL12 stimulation
of MSC migration [55, 56]. Additionally, MSCs express a
variety of receptors, including various integrins and
selectins, that allow extravasation at repair sites [57].
Clues to the mechanisms of MSC trophic activities
(Fig. 1) can also be found in the extensive work done in
other fields, particularly exploration of the stem cell
secretome in the cardiac field [58]. Identified factors
include adrenomedullin, angiogenin, fibroblast growth
factor-2 (FGF2), CXCL12, cistatin C, cysteine-rich angio-
genic inducer 61 (Cyr61), Dickkopf-related proteins (Dkk),
hepatocyte growth factor (HGF), insulin-like growth factor
(IGF), IL-1, IL-6, pigmented epithelium-derived factor
(PEDF), placental growth factor (PLGF), SDF1, TSG6,
VEGF, MMP-2, tissue inhibitor of metalloproteinase-1
(TIMP-1), TIMP-2, secreted frizzled related protein-2
(SFRP-2), thrombospondin-1, and tenascin C [58]. Belying
their osseous origin, CM of BM-MSC appears enriched in
molecules typically secreted by or influencing osteoblasts,
including decorin, osteoprotegerin, Dkk-3, receptor activa-
tor of nuclear factor-kB (RANK), osteopontin, and CCL5;
inflammatory factors maximally produced by BM-MSCs
include CCL2, TIMP-2, IL-6, IL-7, IL-3, MMP-7, chemo-
kine (C-X-C) receptor-16 (CXCR16), and MMP-10. CCL2
and CCL7 produced by BM-MSCs appear to strongly in-
fluence nascent bone formation [59, 60]. Recent work also
suggests that AD-MSC, BM-MSC, and dental pulp stem
cell-secreted CXCL14 and CCL2 help to recruit CXCR4+
cells and chemokine (C-C) receptor-2+ (CCR2+) vessel-
associated cells, without inducing proliferation [61]. Be-
sides these influential but potentially short-lived proteins,
some MSCs secrete EVs which may contain any number
of influential molecules, protected from systemic degrad-
ation by virtue of their natural, membrane-bound pack-
aging [62–65].
In many cell types, EVs of varying sizes, including
ectosomes/exosomes and microvesicles/microparticles,
were derived from either cytoplasmic protrusions or
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Cell sources Observed trophic activity Mechanistic insights
Angiogenesis [84] IV Human BM-MSCs; UCB-ECs MSCs encouraged EC migration,
proliferation, and tubule formation
GHK (osteonectin peptide) induces
MSC-VEGF secretion
Angiogenesis [81] IV Human BM-MSCs (commercial);
microvascular ECs
MSC culture on stiff, fibronectin-
coated surfaces encouraged EC
spreading/tubule formation
Actomyosin contractility increased
MSC expression of proangiogenic
factors (angiogenin, VEGF, and IGF)
Angiogenesis [105] IV Human BM-MSCs (commercial);
UV-ECs
EC-MSC coculture increased MSC-
myogenic and EC-PLAU, EC-FGF, and
EC-NF-kB-regulated gene expression
• MSC IL-1β and IL-6 regulate EC
NF-kB target genes, including
P-selectin, CCL23, and CXCL2/3
• EC TGF-β1/3 may regulate MSC
myogenic differentiation
Angiogenesis [107] IV/mouse Human BM-MSCs (commercial);
UV-ECs
• IV: EC-MSC (vs EC) cultures on de-
gradable scaffolds expressed higher
perivascular markers
IV: cocultures upregulated VEGF and
ANG1 while downregulating ANG2
• Host angiogenic and perivascular
markers, except vessel diameter
and density, were equivalent
between EC/MSC-EC implants
Angiogenesis [73] IV/mouse Human iMSCs (medium change of
iPSCs); UV-ECs
• iMSC exosomes promoted EC
migration, proliferation, and dose-
dependent tubule formation (IV)
iMSCs induced EC expression of
proangiogenic molecules, including
VEGF, TGF-β1, and ANG1
• Exosome treatment correlated with
modest functional improvement,
better perfusion and tissue damage




Mouse Mouse AD-MSCs (plastic adherence);
BM-MSCs (plastic adherence);
BM-iMSCs (immunodepletion)
• BM-MSCs maximally decreased
inflammatory cell invasion
IV: BM-MSCs expressed the highest
levels of tested chemokines, vessel
stabilizing, and matrix-remodeling








Rat Human AD-MSCs (plastic adherence);
DRG; UV-EC
• Medium cocktail-stimulated MSCs
enhanced DRG neurite extension
and EC-tubule formation
Stimulated MSCs produced increased
VEGF, ANG1, NGF, BDNF, and GDNF
• Stimulated and unstimulated MSCs
encouraged neurite extension
Neurogenesis [167] IV Rat BM-MSCs (plastic adherence) Spinal cord tissue–MSC coculture
supported neurite outgrowth
Cocultured MSCs produced NGF,





Rat Rat BM-MSCs (commercial) MSC-treated rats displayed
decreased hyperalgesia and
increased pain threshold
TUBB3–, GFAP–, and αSMA– and
STRO1+ MSCs engrafted into DRGs
Neurogenesis
(sciatic crush) [124]
Mouse Human AD-MSCs and AM-MSCs
(commercial)
• AM-MSC-treated groups exhibited
higher recovery, coordination, and
perfusion scores (4 weeks)
Nerves injected with AM-MSCs
versus AD-MSCs or PBS produced
more ANG1, FGF1, IGF1, and VEGFA





Mouse Human BM-MSCs (commercial) • MSC and MSC-CM accelerated DO
healing
• IV: IL-3/IL-6/CCL5/SDF1 recruited
mononuclear cells, contributed to
enhanced mineralization
• MSC-CM recruited more vessels
• MCP1/MCP3 but not SDF1 were
critical for SC-CM osteogenic activity
Osteogenesis [168] Mouse Human AD-MSCs and BM-MSCs;
UCB-ECs
• MSC-EC cotransplantation increased
MSC engraftment
PDGFBB/PDGFRβ receptor activity
regulates MSC engraftment and
differentiation in the presence of ECs
• Cotransplantation restricted MSC
multipotency, enhanced MSC source-
related differentiation abilities, and
maintained MSC proliferation capacity
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Mouse Human BM-MSCs and DP-MSCs • MSC injections improved
osteoporosis-related bone scores
IL-17 removal following MSC
injection maintains osteoclast
immaturity
• MSCs lowered osteoclast
differentiation (IV)
Osteogenesis [169] Rat Rat BM-MSCs (centrifugation and
plastic adherence)
Fibrin-loaded MSC recruited host
macrophages to fill long bone defect
by 4 weeks
Implanted MSCs increased early
expression of VEGF and decreased





IV Human BM-MSCs (density gradient)
and human embryonic stem cell
MSCs (medium/substrate changes);
human aortic ECs
MSC-EC cocultures proliferated and
exhibited higher expression of
mesenchymal differentiation
transcription factors
EC-produced ET1 activates MSC AKT,
driving osteogenic and
chondrogenic capacities
Chondrogenesis [95] IV Human BM-MSCs (density gradient) • MSCs and/or chondrocytes in fibrin
gels exhibited superior mechanical
properties to those cultured with
OA cartilage explants
IL-1β and IL-6 decreased COL
production versus control cultures,
except in chondrogenic cultures at
longer culture times (4 weeks)
• COLI/II/III production reduced in
OA cartilage–MSC or chondrocyte–
MSC cocultures











Horse Horse AD-MSCs Lesions were smaller, more
vascularized, and less cellular when
treated with platelet concentrate-
injected MSCs
• Greater amount of RNA was
recovered from the MSC-treated
group






IV Mouse quickly and slowly adhering






and active β-catenin encouraged
nonmyogenic differentiation of
dKO-nmMSCs in gastrocnemius
tissues• dKO vs. WT-nmMSCs differentiated
more efficiently along osteogenic





IV Human AD-MSCs and BM-MSCs
(commercial); Dupuytren’s disease-
derived myofibroblast (DDMF)
• AD-MSCs (similar to normal
skin-derived fibroblasts) decreased
while BM-MSCs increased DDMF
co-culture contractility
AD-MSC/myofibroblast cocultures
exhibited decreased COLI and αSMA
• AD-/BM-MSCs inhibited
myofibroblast proliferation
• AD-MSC effects were strongest
with direct or indirect contact
Musculogenesis
(dystrophin) [160]
Mouse Human (STRO1+) DP-MSCs; human
(c-Kit+) amniotic fluid MSCs
• MSCs differentiated in the presence
of C2C12-formed myotubes (IV)
Demethylation was critical for IV
myogenic differentiation
• MSCs differentiated most efficiently
with C2C12-CM
• All differentiated MSCs engrafted
and improved muscle histology
Musculogenesis
[137]
IV Mouse BM-MSCs (centrifugation and
plastic adherence)
MSC-CM stimulated myoblast and
satellite cell proliferation and
migration, activated satellite cells,
inhibited myofibroblast
differentiation
MSC MMP-2/9 and TIMP-1/2 support
myogenic differentiation
AD, adipose-derived, AM amniotic membrane, BM, bone marrow, CM conditioned medium, dKO double knockout, DP dental pulp, DRG dorsal root ganglia, EC
endothelial cell, iMSCs MSCs generated from induced pluripotent stem cell (iPSC) lines via medium change, IV in vitro, MMP matrix metalloproteinase, MPC multipotent
cell, MSC mesenchymal stem cell, SC stem cell, TIMP tissue inhibitor of metalloproteinase, UCB umbilical cord blood, UV umbilical vein
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lipid raft internalization and subsequent endosomal fu-
sion with the plasma membrane [66–69]. These 30 nm–
1 μm vesicles may be studded with multiple proteins,
usually tetraspanins, and filled with a combination of
proteins, lipids, and copious amounts of mRNA and
microRNA (miRNA), particularly miR22 and miR-19a
[58]. EC and cancer cell-derived microparticles may po-
tently increase MSC NF-kB activity, stimulating local
trophic support [70]. Gap junctions, formed via connex-
ins, are another avenue allowing direct cell–cell com-
munication, with strong evidence for membrane and (to
a lesser extent) cytoplasmic exchange between MSCs
and ECs [71].
Likely mediated through EC-stimulated VEGF produc-
tion, CXCR4-enriched exosomes derived from MSCs
generated from induced pluripotent stem cell (iPSC)
lines via medium change (iMSCs) improved recovery
from myocardial infarction [72]. In work addressing
hindlimb ischemia in mice, iMSC exosomes were associ-
ated with a higher number of CD31+ and CD34+ cells in
damaged muscle tissue as well as increased EC secretion
of VEGF, TGF-β1, and angiogenin, suggesting enhanced
vascular recruitment by vesicles alone [73]. Another
group generated iMSCs through TGF-β-pathway in-
hibition and medium changes; those iMSCs, surpris-
ingly, did less to promote cancer than BM-MSCs,
appearing to express and produce lower amounts of
several of the inflammatory and differentiation factors
(particularly TGF-β receptor-2 and, interestingly, hya-
luronan (HA)) when cultured with various types of
cancer cells [74].
In a recent study, Baglio et al. [75] characterized the
RNA contents of exosomes obtained through ultracen-
trifugation, and found that exosomes were enriched for
tRNA, in particular tRNA CTC. Their work further sug-
gested that the differentiation state of a MSC might be
deduced by the content of its exosomes, particularly the
presence of full-length tRNA and tRNA long fragments,
consistent with a stem-like state of the cells [76]. miRNA
loading within vesicles is not random, as dexamethasone
treatment of both C2C12 cells and diabetic rats in-
creased the concentration of miR-23a and miR-182 in
collected microvesicles and urine, respectively [77], thus
providing MSCs with a dynamic way to influence and
respond to their microenvironment. Microvesicles may
also suppress the infiltration of macrophages into dam-
aged tissues [75]. However, the relevance of vesicles/
microvesicles to classical and clinically approved MSCs
is questionable, because a different group noted that
MSCs produced much fewer vesicles than immortalized
ESC-derived MSCs [78]. The group offered an immor-
talization strategy that would maximize the yield of MSC-
produced vesicles, should they prove effective in the
clinic.
Fig. 1 MSC trophic mechanisms depend on MSC interactions with and modification of the local environment. MSC trophic functions can be
both achieved and altered through dynamic ECM–cytoskeletal interactions, cell–cell contacts, and soluble and transcription factor signaling. ECM
extracellular matrix, miRNA microRNA, MMP matrix metalloproteinase, MSC mesenchymal stem cell, TIMP tissue inhibitor of metalloproteinase
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Altering MSC activity prior to bone or cartilage
implantation
Because “plain” MSC implantation has faced such varied
success in the clinic, the next generation of MSC-based
strategies seeks to harness and direct MSC trophic activ-
ities. It was observed that substrate composition and
stiffness, sensed through various integrins, could influ-
ence the expression of myogenic factors [79]. Substrate
stiffness, known to affect the differentiation of MSCs,
acting possibly through regulation of alpha-smooth
muscle actin (αSMA), could also play a role in the even-
tual differentiation capacity of culture-expanded MSCs
[80]. Substrate stiffness, in turn, affects MSC trophic
properties; stiff (40 kPA) polyacrylamide gels coated with
fibronectin induced proangiogenic factor secretion by
BM-MSCs [81]. Through internalization and recycling of
focal adhesions and receptors, caveolins play an intri-
guing role in MSC sensing of both substrate stiffness
and surrounding soluble signals, particularly in vascular,
muscular, and osteogenic settings [82]. Alternatively,
hydrogels made from autologous plasma may also help
to temporarily concentrate either AD-MSCs or AD-MSC-
CM at the injury site [83].
The ability of MSCs to self-generate abundant collage-
nous extracellular matrix (ECM) may partially explain
some of the positive effects witnessed in some joint
degeneration trials involving MSCs [27]. Medium sup-
plements or additional modifications to the substrate to
mimic other ECM molecules or bioactive factors, such
as osteonectin, may further increase MSC secretion of
bioactive molecules (FGF2, CCL5, and VEGF), supporting
native cell migration and differentiation [84].
The milieu present in culture serum appears to
strongly influence the fate of cultured cells, more so
than any single exogenous supplement [85]. One method
to both encourage MSC trophic activity as well as ease
immunological concerns in the clinic could be to utilize
autologously derived cell culture supplements such as
platelet lysate for autologous MSC expansion and cul-
ture [86]. Platelet-rich plasma, for example, may protect
cartilage from injury by enhancing collagen II (COLII)/
aggrecan (AGN) expression and suppressing MMP-3,
COX2, iNOS, and associated NO and PGE2 production
[87]. Once established in vitro, however, the role of
serum becomes less clear; while serum content affects
MSC gene expression and growth rate, inherent multi-
potency and stem cell marker surface expression do not
appear to be affected by the absence of serum [88]. For
that reason, MSC-CM concentration and injection may
sidestep issues of autophagy [89] or apoptosis of MSCs
upon in-vitro expansion [13].
Culture under hypoxia is another attractive method to
increase initial MSC production of trophic factors.
Under hypoxia, hypoxia inducible factor-1 alpha (HIF1α)
expression increases, driving VEGF and other proangio-
genic, antiapoptotic, and antioxidant molecules [90].
Under certain circumstances, hypoxic MSCs may serve
to prevent harmful fibrosis through HGF production,
TGF-β1/COLII, and IL-1β downregulation, and fibro-
nectin expression [91]. Work in vitro with chondrocytes
has specifically identified HGF as an antifibrotic agent
released by AD-MSCs [92]. Furthermore, FGF1 secreted
by MSCs in contact with chondrocytes may stimulate
the proliferation of and help to preserve the function of
chondrocytes [93, 94].
In-vitro evidence suggests that the addition of BM-
MSCs to OA cartilage may initially increase IL-1β and
IL-8 production but ultimately reduce the amount of
soluble glycosaminoglycan (GAG) released by the cartil-
age over time, making the exact influence of MSCs on
cartilage structure unclear [95].
Reported pain relief associated with the introduction
of MSCs may be the result of immunomodulation but
was by no means universal [36]. In-vitro studies suggest
that exposure of MSCs to chondrocytes may induce
expression of MSC major histocompatibility complex
(MHC) I/II and other costimulatory molecules [96].
Pretreatment of MSCs, especially with IFN-γ to prime
their immunosuppressive activity, may result in decreased
MSC-associated tissue degradation [97]. Possibly in re-
sponse to IL-1α, MSCs exposed to platelet lysate have the
capacity to encourage a proinflammatory/M1 or proresol-
ving/M2 macrophage phenotype through GM-CSF and
PGE2 activity, respectively [53, 98]. Growing evidence sug-
gests that the native, inflamed cartilage environment may
both trigger the release and limit the effectiveness of
MSC-anti-inflammatory PGE2 [99]. MSCs may recruit
CD4+ T cells, which can also play a role in increasing local
osteogenic activity [100]. Care must be taken with exten-
sive culture, because MSCs may gain genetic abnormal-
ities and lose some ability to differentiate, promoting
senescence [88].
Vascular/inflammation regulation
Several key targets of regenerative medicine therapies,
including restored nerve and muscle function and the
previously discussed bone repair, rely heavily on the
influence of vascular cells [101]. Consequently, MSC
effects on blood vessel cells have long fascinated re-
searchers. Recent work has begun to elucidate mechanisms
by which MSCs may affect blood vessel morphology and
function. Chen et al. [102] reported that MSC-produced
HGF, upon interaction with ECs in coculture and, to a
lesser extent, via paracrine signaling, caused an increase in
EC cadherin and F-actin remodeling, thereby decreasing
EC permeability [90, 103, 104]. This and earlier work with
ECs suggests that MSC–EC interactions may temporarily
restrict both the physical clearance of MSCs and the
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invasion of inflammatory cells. Once in the bloodstream,
MSC inhibition of NF-kB, perhaps through IL-10 or other
factors, may decrease the binding of monocytes to the
endothelium, further decreasing inflammation at wound/
MSC injection sites [45]. This temporary pause in the
battle with chronic inflammation may explain some of the
positive results seen with MSCs.
Following a more classical approach focused on EC
motility and activity, VEGF, ANG, and NF-kB pathways
have all been implicated in regulating angiogenesis. Re-
cent work suggests that, in the short term, the NF-kB
pathway may control EC response through BM-MSC-
produced IL-6 and IL-1β; following this NF-kB activa-
tion, ECs activate P-selectin, producing CCL23, CXCL2,
and CXCL3. In turn, MSCs showed signs of early differ-
entiation towards a smooth muscle phenotype in cocul-
ture, influenced by TGF-β1 and TGF-β3 [105]. BM-MSC
production of VEGF may be stimulated by IL-8, either
through paracrine or autocrine mechanisms [106]. In turn,
BM-MSCs may stabilize ECs by upregulating ANG1,
thereby downregulating EC proliferation [107]. Con-
versely, the interaction of MSCs with ECs, particularly
through endothelin 1 (ET1) and PDGFB, may prime cells
to survive transplantation and differentiate more easily
upon reimplantation [108].
Neural support
MSCs have long been known to support nerve growth
through the support of Schwann cells, secretion of
neurovascular factors (including FGF2 and VEGF-A),
and, possibly, transdifferentiation into Schwann-like
cells. Combined with varying types of biocompatible and
bioactive materials, such as poly-lactic acid (PLA), poly-
caprolactone (PCL), polyurethane (PU), polyethylene
(PE), and silicone (for strength) and COLI, HA, and so
forth (for bioactivity), several groups have observed en-
hanced nerve extension and functional improvements in
a range of animal models [109, 110]. The most recent
work refines previous findings that guidance fibers of
particular spacing and architecture may aid MSCs in fur-
ther accelerating the nerve healing process [111–113].
AD-MSCs, at sufficient density, secrete brain-derived
neurotrophic factor (BDNF) in response to autocrine
IFN-β [114]. Stimulating cocktails that increase cyclic-
adenosine monophosphate (cAMP) and include retinoic
acid (pretreatment), FGF2, PDGFAA, and different forms
of neuregulin have been shown to increase neurite out-
growth in vitro and nerve extension after injury in vivo
[115]. In addition to neurotrophic BDNF, nerve growth
factor (NGF), and glial cell line-derived neurotrophic fac-
tor (GDNF), as well as angiogenic VEGF and ANG1 iden-
tified in many other experiments, recent work identified
the antiapoptotic activity of AD-MSCs, possibly by de-
creasing neuronal c-jun [116]. As mentioned in previous
sections, such pretreatment is relatively common in non-
clinical work, and may become de rigeur as new progeni-
tor cell sources are explored for musculoskeletal therapies
[117]. Crucially, it appears that MSCs should not be dir-
ectly injected intrathecally for early spinal cord repair, as
the subsequent inflammation seemed to prevent MSC mi-
gration to neuronal injury sites [118]; later injection may
prove beneficial [119].
Ciliary neurotrophic factor (CNTF) is a particularly
well known neuroprotective factor produced by MSCs.
While the factor has potent therapeutic effects on nerve
apoptosis, neuroinflammation, and neuronal prolifera-
tion, it has been linked with altered metabolism (due to
neurogenesis in the hypothalamus as well as direct ac-
tion on adipocytes) when administered systemically and
may negatively affect osteoblast differentiation and
mineralization [120–122]. GDNF, another potent neuro-
trophic molecule often produced by MSCs, may help to
ease allodynia and hyperalgesia experienced in dorsal
root ganglia sensory nerves [123]. Amniotic membrane-
derived MSCs expressed more ANG1, FGF1, IGF1, and
VEGFA (but not FGF2) than AD-MSCs in a mouse
sciatic nerve injury trial [124].
While CM from cells treated under hypoxic and
normoxic conditions both increased the observed num-
ber of differentiating neurons in vitro, hypoxia-cultured
Wharton’s Jelly (WJ)-derived MSCs upregulated thymo-
sin B and eukaryotic elongation factor (EF2) and may
have contributed to a slight increase in total neuron ma-
turity [125]. WJ-MSCs under normoxic conditions were
shown to produce PDGFAA, HGF, TGF-β2, IL-6, IL-8,
IL-1ra, CCL5, CCL2, and CXCL10 at much larger con-
centrations than BM-MSCs and AD-MSCs [126]. What-
ever the mechanism for neural support, tissue response
to neurological directives is critical to the ultimate utility
of the repaired nerve.
Muscles and miscellany
Intriguing results suggest that MSCs derived from less
traditional sources could one day be utilized therapeutic-
ally. One readily available source for MSCs could be
skeletal muscles. Our research group has worked exten-
sively with blast-traumatized muscle-derived multipotent
cells [127–129]. This particular type of muscle-derived
multipotent cells is especially attractive therapeutically
due to its relative abundance and ease of isolation [130]
as well as neurotrophic activity [131]. MDSCs should be
used cautiously when attempting to rebuild musculo-
skeletal tissues, because several groups have identified
populations that seem predisposed to mineralize ectopi-
cally [132–134], especially in the presence of muscular
genetic abnormalities [135]. Growth factor coinjection
might attenuate this ectopic bone formation, as growth
hormone–insulin-like growth factor-1 (GH-IGF1) activity
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promotes muscle cell proliferation, regulates muscle fiber
size and type, controls osteoblast proliferation and differ-
entiation, inhibits osteoclast activity, stimulates renal con-
version of 25-OH-vitamin D3, and controls phosphate
reabsorption [136]. By contrast, this matrix-modifying
MSC activity may help to attenuate disease severity and
ultimately contribute to useful muscle mass [137]. Harm-
ful proliferation and contraction of myofibroblasts, as oc-
curs in Dupuytren's contracture, may be attenuated in the
presence of the CM of both AD-MSCs or BM-MSCs as
well as the physical presence of AD-MSCs (but not
BM-MSCs) [138]. BM-MSCs appear to contribute to
pathological myofibroblast proliferation while AD-
MSCs appear to inhibit the activity slightly [138].
MMP-2 and MMP-9 are required for efficient skeletal
muscle regeneration and are enhanced by mouse BM-
MSCs/MSC-CM along with reduced TIMP-1/2 levels.
Muscle cell motility may also be encouraged by BM-MSC-
secreted MMP-2 [139].
Aside from their ECM-modifying properties, the
immunomodulatory properties of MSCs are intriguing
from a therapeutic standpoint but must be used carefully,
because MSC treatment, concurrent with a Staphylococcus
aureus infection, was shown to increase the severity of
bone loss, despite increased MSC proinflammatory cyto-
kine expression, in an osteomyelitis model [140]. Con-
versely, encouraging results were recently published from
a small idiopathic osteonecrosis trial in Japan, where BM-
MSCs were isolated, cultured for 2 weeks, and returned to
osteonecrotic patients along with tricalcium phosphate
chips (Osferion) and tricortical iliac crest bone [141]; after
a 12-week rehabilitation program, all patients reported
reduced pain and increased physical function with no
serious adverse events reported in the study [142]. The
likelihood of MSC engraftment being the cause for the
recovery is low, however, as MSCs have been found to
migrate towards apoptotic cells, via HGF signaling, but
not HGF produced in the presence of necrotic cells [143].
Evidence of MSC trophic efficacy has generated in-
tense excitement in clinically focused research. This ex-
citement is evident in the increasing number of reviews
examining MSC trophic properties. Marked therapeutic
successes will likely hinge on technological and computa-
tional advancements that allow dynamic, high-resolution,
and quantitative observation of MSC–ECM, MSC–para-
crine, and MSC–cellular interactions to better define the
appropriate perspective on the true activity of MSCs.
Conclusions
The application of allogeneic and autologous MSC ther-
apies for the treatment of diseases and dysfunctions of
multiple musculoskeletal tissues has received increasing
attention. Exciting in-vitro and in-vivo investigations on
tendon [117, 144, 145], meniscus [146–148], and ligaments
[149, 150] have been reported, along with the use of
autologous products such as platelet-rich plasma/plasma
lysate [151]. Studies using larger, clinically relevant animal
models are both underway and necessary before human
clinical trials can be developed [152].
This review has primarily explored secreted trophic
factors produced by MSCs. A whole host of therapies
are dedicated to engineering or modifying the physical
environment and ECM of MSCs to affect their therapeutic
potential. A recently developed approach attempts to an-
chor cells to the collagenous tissue matrix by engineering
collagen anchors [153], to promote local action of MSCs
and minimize their systemic loss to the lungs, liver, and
spleen. Changes in substrate composition (especially the
presence of collagen) and stiffness may expand the po-
tential applications of MSC therapies to include muscle
volume loss through stimulation of muscle-resident pro-
genitor cells [134, 154, 155]. Local ECM modifications are
known to affect MSC differentiation potential [156, 157]
and are beyond the scope of this review. Through con-
tinuing advancements in genetic engineering, MSCs may
eventually be used to treat genetic musculoskeletal
conditions, including osteogenesis imperfect [158] and
Duchenne’s muscular dystrophy [159, 160]. Careful se-
lection of the therapeutic cells, taking into account
subtle tissue source-related differences, may be the
key to successful clinical dystrophy therapies [35]. To
prove their efficacy in the clinic, these potential treat-
ments will need to be tested in well-controlled studies
to assess physical functions for an extended period of
time [27].
New or more precise modes of MSC trophic activity
may be discovered by adopting contemporary analytical
technologies to evaluate and compare genomic, tran-
scriptomic, proteomic, metabolomic, and secretomic
profiles, exemplified by the great strides that have been
made in genetic and metabolic diseases [161–164]. Les-
sons learned from previous iterations of MSC therapies
and clinical drug trials should overcome some of the regu-
latory and therapeutic hurdles to MSC use [2, 32, 33]. It is
also noteworthy that while genetic engineering of iPSCs
may hold the answer to unlimited numbers of perfectly-
tuned stem cells, managing the safety concerns of iPSCs
and negotiating the patent landscape of this saturated
market will be highly challenging [165]. Another major
challenge is the uncertainty in terms of biological respon-
siveness of the diseased tissue, because evidence in several
fields suggests that ischemic tissue may be incapable of
responding to MSCs [166]. Finally, each of these ave-
nues should be explored while juggling the needs for
rigorous science, proven therapeutic efficacy, regula-
tory approval (e.g., by the Food and Drug Agency)
(and thus reproducibility) of a final therapy, and cost/
benefit for the patient.
Hofer and Tuan Stem Cell Research & Therapy  (2016) 7:131 Page 10 of 14
Acknowledgements
This work is supported in part by the Commonwealth of Pennsylvania
Department of Health (SAP 4100050913), NIH (5U18 TR000532), and US
Department of Defense (W81XWH-08-2-0032, W81XWH-14-2-0003). A portion
of the predoctoral training of HRH was supported by a Training Grant funded
by the National Institute of Biomedical Imaging and Bioengineering, NIH
(T32EB0010216). HRH acknowledges the faculty, staff, and students of CCME,
where HRH served as a Research Fellow during a portion of the time
required to draft and edit this document.
Authors’ contributions
HRH created the figure and tables, and researched, drafted, and arranged the
document. RST suggested the content, edited the document, and was the
invited, corresponding author. Both authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
References
1. Wei C, Lin AB, Hung S. Mesenchymal stem cells in regenerative medicine
for musculoskeletal diseases: bench, bedside, and industry. Cell Transplant.
2014;23:505–12.
2. Heathman TR, Nienow AW, McCall MJ, Coopman K, Kara B, Hewitt CJ. The
translation of cell-based therapies: clinical landscape and manufacturing
challenges. Regen Med. 2015;10:49–64.
3. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in
transplants of bone marrow cells. J Embryol Exp Morphol. 1966;16:381–90.
4. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–50.
5. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
et al. Minimal criteria for defining multipotent mesenchymal stromal cells
The International Society for Cellular Therapy position statement.
Cytotherapy. 2006;8:315–7.
6. Salem HK, Thiemermann C. Mesenchymal stromal cells: current
understanding and clinical status. Stem Cells. 2010;28:585–96.
7. Dmitrieva RI, Minullina R, Bilibina AA, Tarasova OV, Anisimov SV, Zaritskey
AY. Bone marrow- and subcutaneous adipose tissue-derived mesenchymal
stem cells: differences and similarities. Cell Cycle. 2012;11:377–83.
8. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Evidence for CD34
as a common marker for diverse progenitors. Stem Cells. 2014;32:1380–9.
9. Lv F-J, Tuan RS, Cheung KMC, Leung VYL. The surface markers and identity
of human mesenchymal stem cells. Stem Cells. 2014;32:1408–19.
10. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11–5.
11. Vonk LA, de Windt TS, Slaper-Cortenbach ICM, Saris DBF. Autologous,
allogeneic, induced pluripotent stem cell or a combination stem cell
therapy? Where are we headed in cartilage repair and why: a concise
review. Stem Cell Res Ther. 2015;6:1–11.
12. Ruetze M, Richter W. Adipose-derived stromal cells for osteoarticular repair:
trophic function versus stem cell activity. Expert Rev Mol Med. 2014;16:e9.
13. Liang X, Ding Y, Zhang Y, Tse H, Lian Q. Paracrine mechanisms of
mesenchymal stem cell-based therapy: current status and perspectives.
Cell Transplant. 2014;23:1045–59.
14. Caplan AI, Sorrell JM. The MSC curtain that stops the immune system.
Immunol Lett. 2015;168:136–9.
15. Diederichs S, Shine KM, Tuan RS. The promise and challenges of stem
cell-based therapies for skeletal diseases. Bioessays. 2013;35:220–30.
16. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of
human mesenchymal stem cells (MSC): a comparison of adult and neonatal
tissue-derived MSC. Cell Commun Signal. 2011;9:1–14.
17. Mahdi NS, Rahbarghazi R. Interactions of mesenchymal stem cells with
endothelial cells. Stem Cells Dev. 2014;23:319–32.
18. Tamaki T, Okada Y, Uchiyama Y, Tono K, Masuda M, Wada M, et al. Clonal
multipotency of skeletal muscle-derived stem cells between mesodermal
and ectodermal lineage. Stem Cells. 2007;25:2283–90.
19. Zou J, Yuan C, Wu C, Cao C, Shi Q, Yang H. Isolation and osteogenic
differentiation of skeletal muscle-derived stem cells for bone tissue
engineering. Mol Med Rep. 2013;9:185–91.
20. Meszaros LB, Usas A, Cooper GM, Huard J. Effect of host sex and sex
hormones on muscle-derived stem cell-mediated bone formation and
defect healing. Tissue Eng Part A. 2012;18:1751–9.
21. De Ceuninck F, Fradin A, Pastoureau P. Bearing arms against osteoarthritis
and sarcopenia: when cartilage and skeletal muscle find common interest
in talking together. Drug Discov Today. 2014;19:305–11.
22. Bortolotti F, Ukovich L, Razban V, Martinelli V, Ruozi G, Pelos B, et al. In vivo
therapeutic potential of mesenchymal stromal cells depends on the source
and the isolation procedure. Stem Cell Reports. 2015;4:332–9.
23. Krylova TA, Musorina AS, Zenin VV, Yakovleva TK, Poljanskaya GG. A
comparative analysis of mesenchymal stem-cell lines derived from bone
marrow and limb muscle of early human embryos. Cell Tissue Biol.
2014;8:441–53.
24. Baker N, Boyette LB, Tuan RS. Characterization of bone marrow-derived
mesenchymal stem cells in aging. Bone. 2015;70:37–47.
25. Verdi J, Tan A, Shoae-Hassani A, Seifalian AM. Endometrial stem cells in
regenerative medicine. J Biol Eng. 2014;8:20.
26. Alcayaga-Miranda F, Cuenca J, Luz-Crawford P, Aguila-Díaz C, Fernandez A,
Figueroa FE, et al. Characterization of menstrual stem cells: angiogenic
effect, migration and hematopoietic stem cell support in comparison with
bone marrow mesenchymal stem cells. Stem Cell Res Ther. 2015;6:1–14.
27. Grässel S, Lorenz J. Tissue-engineering strategies to repair chondral and
osteochondral tissue in osteoarthritis: use of mesenchymal stem cells.
Curr Rheumatol Rep. 2014;16:1–16.
28. Centeno C, Pitts J, Al-Sayegh H, Freeman M. Efficacy of autologous bone
marrow concentrate for knee osteoarthritis with and without adipose graft.
Biomed Res Int. 2014;2014:370621.
29. Mobasheri A, Kalamegam G, Musumeci G, Batt ME. Chondrocyte and
mesenchymal stem cell-based therapies for cartilage repair in osteoarthritis
and related orthopaedic conditions. Maturitas. 2014;78:188–98.
30. Baugé C, Boumédiene K. Use of adult stem cells for cartilage tissue
engineering: current status and future developments. Stem Cells Int.
2015;2015:438026.
31. Boregowda SV, Phinney DG. Therapeutic applications of mesenchymal stem
cells: current outlook. BioDrugs. 2012;26:201–8.
32. Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal
cells: a review of clinical applications and manufacturing practices.
Transfusion. 2014;54:1418–37.
33. Srijaya TC, Ramasamy TS, Kasim NHA. Advancing stem cell therapy from
bench to bedside: lessons from drug therapies. J Transl Med. 2014;12:243.
34. Wang R, Rao MS. Application of mesenchymal stem cells in joint diseases.
OA Musculoskelet Med. 2013;1:26.
35. Farini A, Sitzia C, Erratico S, Meregalli M, Torrente Y. Clinical applications
of mesenchymal stem cells in chronic diseases. Stem Cells Int.
2014;2014:306573.
36. Counsel PD, Bates D, Boyd R, Connell DA. Cell therapy in joint disorders.
Sports Health. 2014;7:27–37.
37. Mendonça MV, Larocca T, de Freitas SB, Villarreal C, Silva LF, Matos A, et al.
Safety and neurological assessments after autologous transplantation of
bone marrow mesenchymal stem cells in subjects with chronic spinal cord
injury. Stem Cell Res Ther. 2014;5:126.
38. Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J.
Intervertebral disc repair by autologous mesenchymal bone marrow cells: a
pilot study. Transplantation. 2011;92:822–8.
39. Kovacs FM, Abraira V, Gérvas J, Arana E, Peul WC, Schoene ML, et al.
Overenthusiastic interpretations of a nonetheless promising study.
Transplantation. 2012;93:e6–7.
40. Itescu S. Mesoblast—a global leader in cell based medicines. In: 34th
Annual J.P. Morgan Healthcare Conference; San Francisco, CA; January 2016.
41. Behrens F, Tak PP, Ostergaard M, Stoilov R, Wiland P, Huizinga TW, et al.
MOR103, a human monoclonal antibody to granulocyte-macrophage
colony-stimulating factor, in the treatment of patients with moderate
rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind,
placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2014;74:1058–64.
42. De Bari C. Are mesenchymal stem cells in rheumatoid arthritis the good or
bad guys? Arthritis Res Ther. 2015;17:113.
43. Lefèvre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, et al.
Synovial fibroblasts spread rheumatoid arthritis to unaffected joints.
Nat Med. 2009;15:1414–20.
44. El-Jawhari JJ, El-Sherbiny YM, Jones EA, McGonagle D. Mesenchymal stem
cells, autoimmunity and rheumatoid arthritis. QJM. 2014;107:505–14.
Hofer and Tuan Stem Cell Research & Therapy  (2016) 7:131 Page 11 of 14
45. Letourneau PA, Menge TD, Wataha KA, Wade CE, S Cox C, Holcomb JB, et
al. Human bone marrow derived mesenchymal stem cells regulate
leukocyte-endothelial interactions and activation of transcription factor
NF-kappa B. J Tissue Sci Eng. 2011;Suppl 3:001.
46. Carrillo-Galvez AB, Cobo M, Cuevas-Ocaña S, Gutiérrez-Guerrero A,
Sánchez-Gilabert A, Bongarzone P, et al. Mesenchymal stromal cells express
GARP/LRRC32 on their surface: effects on their biology and
immunomodulatory capacity. Stem Cells. 2015;33:183–95.
47. Maumus M, Jorgensen C, Noël D. Mesenchymal stem cells in regenerative
medicine applied to rheumatic diseases: role of secretome and exosomes.
Biochimie. 2013;95:2229–34.
48. Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid AA, Mardani K.
Microvesicles derived from mesenchymal stem cells: potent organelles for
induction of tolerogenic signaling. Immunol Lett. 2012;147:47–54.
49. Ottoboni L, De Feo D, Merlini A, Martino G. Commonalities in immune
modulation between mesenchymal stem cells (MSCs) and neural stem/
precursor cells (NPCs). Immunol Lett. 2015;168:228–39.
50. Jiang Y, Tuan RS. Origin and function of cartilage stem/progenitor cells in
osteoarthritis. Nat Rev Rheumatol. 2014;11:206–12.
51. Uth K, Trifonov D. Stem cell application for osteoarthritis in the knee joint: a
minireview. World J Stem Cells. 2014;6:629–36.
52. Czekanska EM, Czekanska EM, Ralphs JR, Alini M, Stoddart MJ. Enhancing
inflammatory and chemotactic signals to regulate bone regeneration.
Eur Cells Mater. 2014;28:320–34.
53. Ulivi V, Tasso R, Cancedda R, Descalzi F. Mesenchymal stem cell paracrine
activity is modulated by platelet lysate: induction of an inflammatory
response and secretion of factors maintaining macrophages in a
proinflammatory phenotype. Stem Cells Dev. 2014;23:1858–69.
54. Maijenburg MW, van der Schoot CE, Voermans C. Mesenchymal stromal
cell migration: possibilities to improve cellular therapy. Stem Cells Dev.
2012;21:19–29.
55. Gomez-Rodriguez V, Orbe J, Martinez-Aguilar E, Rodriguez JA, Fernandez-
Alonso L, Serneels J, et al. Functional MMP-10 is required for efficient tissue
repair after experimental hind limb ischemia. FASEB J. 2015;29:960–72.
56. Bobadilla M, Sainz N, Abizanda G, Orbe J, Rodriguez JA, Páramo JA, et al.
The CXCR4/SDF1 axis improves muscle regeneration through MMP-10
activity. Stem Cells Dev. 2014;23:1417-27.
57. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal
stem cells: their phenotype, differentiation capacity, immunological features,
and potential for homing. Stem Cells. 2007;25:2739–49.
58. Gallina C, Turinetto V, Giachino C. A new paradigm in cardiac
regeneration: the mesenchymal stem cell secretome. Stem Cells Int.
2015;2015:765846.
59. Ando Y, Matsubara K, Ishikawa J, Fujio M, Shohara R, Hibi H, et al. Stem cell-
conditioned medium accelerates distraction osteogenesis through multiple
regenerative mechanisms. Bone. 2014;61:82–90.
60. Ma L, Aijima R, Hoshino Y, Yamaza H, Tomoda E, Tanaka Y, et al.
Transplantation of mesenchymal stem cells ameliorates secondary
osteoporosis through interleukin-17-impaired functions of recipient bone
marrow mesenchymal stem cells in MRL/lpr mice. Stem Cell Res Ther.
2015;6:104.
61. Hayashi Y, Murakami M, Kawamura R, Ishizaka R, Fukuta O, Nakashima M.
CXCL14 and MCP1 are potent trophic factors associated with cell migration
and angiogenesis leading to higher regenerative potential of dental pulp
side population cells. Stem Cell Res Ther. 2015;6:111.
62. Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al.
Exosome can prevent RNase from degrading microRNA in feces. J
Gastrointest Oncol. 2011;2:215–22.
63. Subra C, Grand D, Laulagnier K, Stella A, Lambeau G, Paillasse M, et al.
Exosomes account for vesicle-mediated transcellular transport of activatable
phospholipases and prostaglandins. J Lipid Res. 2010;51:2105–20.
64. Borges FT, Reis LA, Schor N. Extracellular vesicles: structure, function,
and potential clinical uses in renal diseases. Braz J Med Biol Res.
2013;46:824–30.
65. Katsuda T, Kosaka N, Takeshita F, Ochiya T. The therapeutic potential of
mesenchymal stem cell-derived extracellular vesicles. Proteomics.
2013;13:1637–53.
66. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion
between extracellular vesicles. Trends Cell Biol. 2015;25:364–72.
67. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and
friends. J Cell Biol. 2013;200:373–83.
68. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, et al. Membrane
vesicles, current state-of-the-art: emerging role of extracellular vesicles.
Cell Mol Life Sci. 2011;68:2667–88.
69. Tan SS, Yin Y, Lee T, Lai RC, Yeo RWY, Zhang B, et al. Therapeutic MSC
exosomes are derived from lipid raft microdomains in the plasma
membrane. J Extracell Vesicles. 2013;2:22614.
70. Lozito TP, Tuan RS. Endothelial and cancer cells interact with mesenchymal
stem cells via both microparticles and secreted factors. J Cell Mol Med.
2014;18:2372–84.
71. Boomsma RA, Geenen DL. Evidence for transfer of membranes from
mesenchymal stem cells to HL-1 cardiac cells. Stem Cells Int.
2014;2014:653734.
72. Kang K, Ma R, Cai W, Huang W, Paul C, Liang J, et al. Exosomes secreted
from CXCR4 overexpressing mesenchymal stem cells promote
cardioprotection via Akt signaling pathway following myocardial infarction.
Stem Cells Int. 2015. doi:10.1155/2015/659890.
73. Hu G, Li Q, Niu X, Hu B, Liu J, Zhou S, et al. Exosomes secreted by human-
induced pluripotent stem cell-derived mesenchymal stem cells attenuate
limb ischemia by promoting angiogenesis in mice. Stem Cell Res Ther.
2015;6:10.
74. Zhao Q, Gregory CA, Lee RH, Reger RL, Qin L, Hai B, et al. MSCs derived
from iPSCs with a modified protocol are tumor-tropic but have much less
potential to promote tumors than bone marrow MSCs. Proc Natl Acad
Sci U S A. 2015;112:530–5.
75. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Pérez Lanzón M, Zini N, et
al. Human bone marrow- and adipose-mesenchymal stem cells secrete
exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res
Ther. 2015. doi:10.1186/s13287-015-0116-z.
76. Hudson M, Woodworth-Hobbs M, Rahnert J, Zheng B, Price S.
Glucocorticoids reduce muscle atrophy-related microRNAs via exosomal
microRNA packaging (11634). FASEB J. 2014;28 Suppl 1:1163.4.
77. Müller G. Microvesicles/exosomes as potential novel biomarkers of
metabolic diseases. Diabetes Metab Syndr Obes. 2012;5:247–82.
78. Chen TS, Arslan F, Yin Y, Tan SS, Lai RC, Choo ABH, et al. Enabling a robust
scalable manufacturing process for therapeutic exosomes through
oncogenic immortalization of human ESC-derived MSCs. J Transl Med.
2011;9:47.
79. Lv H, Li L, Sun M, Zhang Y, Chen L, Rong Y, et al. Mechanism of
regulation of stem cell differentiation by matrix stiffness. Stem Cell Res Ther.
2015;6:103.
80. Talele NP, Fradette J, Davies JE, Kapus A, Hinz B. Expression of α-smooth
muscle actin determines the fate of mesenchymal stromal cells. Stem Cell
Reports. 2015;4:1016–30.
81. Abdeen AA, Weiss JB, Lee J, Kilian KA. Matrix composition and mechanics
direct proangiogenic signaling from mesenchymal stem cells. Tissue Eng
Part A. 2014;20:2737–45.
82. Baker N, Tuan RS. The less-often-traveled surface of stem cells: caveolin-1
and caveolae in stem cells, tissue repair and regeneration. Stem Cell Res
Ther. 2013;4:90.
83. Linero I, Chaparro O. Paracrine effect of mesenchymal stem cells
derived from human adipose tissue in bone regeneration. PLoS One.
2014;9:e107001.
84. Jose S, Hughbanks ML, Binder BYK, Ingavle GC, Leach JK. Enhanced trophic
factor secretion by mesenchymal stem/stromal cells with Glycine-Histidine-
Lysine (GHK)-modified alginate hydrogels. Acta Biomater. 2014;10:1955–64.
85. Tratwal J, Mathiasen AB, Juhl M, Brorsen SK, Kastrup J, Ekblond A. Influence
of vascular endothelial growth factor stimulation and serum deprivation on
gene activation patterns of human adipose tissue-derived stromal cells.
Stem Cell Res Ther. 2015;6:62.
86. Li C, Wu X, Tong J, Yang X, Zhao J, Zheng Q, et al. Comparative analysis of
human mesenchymal stem cells from bone marrow and adipose tissue
under xeno-free conditions for cell therapy. Stem Cell Res Ther. 2015;6:55.
87. Xie X, Ulici V, Alexander PG, Jiang Y, Zhang C, Tuan RS. Platelet-rich plasma
inhibits mechanically induced injury in chondrocytes. Arthrosc J Arthrosc
Relat Surg. 2015;31:1142–50.
88. Bellayr IH, Catalano JG, Lababidi S, Yang AX, Lo Surdo JL, Bauer SR, et al.
Gene markers of cellular aging in human multipotent stromal cells in
culture. Stem Cell Res Ther. 2014;5:59.
89. Nuschke A, Rodrigues M, Stolz DB, Chu CT, Griffith L, Wells A. Human
mesenchymal stem cells/multipotent stromal cells consume accumulated
autophagosomes early in differentiation. Stem Cell Res Ther. 2014;5:140.
Hofer and Tuan Stem Cell Research & Therapy  (2016) 7:131 Page 12 of 14
90. Liew A, O’Brien T. Therapeutic potential for mesenchymal stem cell
transplantation in critical limb ischemia. Stem Cell Res Ther. 2012;3:28.
91. Lan YW, Choo KB, Chen CM, Hung TH, Chen YB, Hsieh CH, et al. Hypoxia-
preconditioned mesenchymal stem cells attenuate bleomycin-induced
pulmonary fibrosis. Stem Cell Res Ther. 2015;6:97.
92. Maumus M, Manferdini C, Toupet K, Peyrafitte JA, Ferreira R, Facchini A,
et al. Adipose mesenchymal stem cells protect chondrocytes from
degeneration associated with osteoarthritis. Stem Cell Res. 2013;11:834–44.
93. Wu L, Leijten J, van Blitterswijk CA, Karperien M. Fibroblast growth factor-1
is a mesenchymal stromal cell-secreted factor stimulating proliferation of
osteoarthritic chondrocytes in co-culture. Stem Cells Dev. 2013;22:2356–67.
94. Song X, Xie Y, Liu Y, Shao M, Wang W. Beneficial effects of coculturing
synovial derived mesenchymal stem cells with meniscus fibrochondrocytes
are mediated by fibroblast growth factor 1: increased proliferation and
collagen synthesis. Stem Cells Int. 2015;2015:926325.
95. Leyh M, Seitz A, Dürselen L, Springorum HR, Angele P, Ignatius A, et al.
Osteoarthritic cartilage explants affect extracellular matrix production and
composition in cocultured bone marrow-derived mesenchymal stem cells
and articular chondrocytes. Stem Cell Res Ther. 2014;5:77.
96. Lohan P, Coleman CM, Murphy JM, Griffin MD, Ritter T, Ryan AE. Changes in
immunological profile of allogeneic mesenchymal stem cells after
differentiation: should we be concerned? Stem Cell Res Ther. 2014;5:99.
97. Crop MJ, Baan CC, Korevaar SS, IJzermans JNM, Pescatori M, Stubbs AP, et al.
Inflammatory conditions affect gene expression and function of human
adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol.
2010;162(I):474–86.
98. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new
mesenchymal stem cell (MSC) paradigm: polarization into a pro-
inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One.
2010;5:e10088.
99. Manferdini C, Maumus M, Gabusi E, Piacentini A, Filardo G, Peyrafitte JA,
et al. Adipose-derived mesenchymal stem cells exert antiinflammatory
effects on chondrocytes and synoviocytes from osteoarthritis patients
through prostaglandin E2. Arthritis Rheum. 2013;65:1271–81.
100. Grassi F, Cattini L, Gambari L, Manferdini C, Piacentini A, Gabusi E, et al.
T cell subsets differently regulate osteogenic differentiation of human
mesenchymal stromal cells in vitro. J Tissue Eng Regen Med. 2016;10:305–14.
101. Faroni A, Mobasseri SA, Kingham PJ, Reid AJ. Peripheral nerve regeneration:
experimental strategies and future perspectives. Adv Drug Deliv Rev.
2014. doi:10.1016/j.addr.2014.11.010.
102. Chen QH, Liu AR, Qiu HB, Yang Y. Interaction between mesenchymal stem
cells and endothelial cells restores endothelial permeability via paracrine
hepatocyte growth factor in vitro. Stem Cell Res Ther. 2015;6:44.
103. Bronckaers A, Hilkens P, Martens W, Gervois P, Ratajczak J, Struys T, et al.
Mesenchymal stem/stromal cells as a pharmacological and therapeutic
approach to accelerate angiogenesis. Pharmacol Ther. 2014;143:181–96.
104. Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber MH, Harting M, et al. Human
mesenchymal stem cells inhibit vascular permeability by modulating
vascular endothelial cadherin/β-catenin signaling. Stem Cells Dev.
2011;20:89–101.
105. Li J, Ma Y, Teng R, Guan Q, Lang J, Fang J, et al. Transcriptional profiling
reveals crosstalk between mesenchymal stem cells and endothelial cells
promoting prevascularization by reciprocal mechanisms. Stem Cells Dev.
2015;24:610–23.
106. Hou Y, Ryu CH, Jun JA, Kim SM, Jeong CH, Jeun SS. IL-8 enhances the
angiogenic potential of human bone marrow mesenchymal stem cells by
increasing vascular endothelial growth factor. Cell Biol Int. 2014;38:1050–9.
107. Pedersen TO, Blois AL, Xue Y, Xing Z, Sun Y, Finne-Wistrand A, et al.
Mesenchymal stem cells induce endothelial cell quiescence and promote
capillary formation. Stem Cell Res Ther. 2014;5:23.
108. Lin RZ, Moreno-Luna R, Zhou B, Pu WT, Melero-Martin JM. Equal modulation
of endothelial cell function by four distinct tissue-specific mesenchymal
stem cells. Angiogenesis. 2012;15:443–55.
109. Kehoe S, Zhang XF, Boyd D. FDA approved guidance conduits and wraps
for peripheral nerve injury: a review of materials and efficacy. Injury.
2012;43:553–72.
110. Tamaki T. Bridging long gap peripheral nerve injury using skeletal
muscle-derived multipotent stem cells. Neural Regen Res. 2014;9:1333–6.
111. Oliveira JT, Bittencourt-Navarrete RE, de Almeida FM, Tonda-Turo C,
Martinez AMB, Franca JG. Enhancement of median nerve regeneration by
mesenchymal stem cells engraftment in an absorbable conduit:
improvement of peripheral nerve morphology with enlargement of
somatosensory cortical representation. Front Neuroanat. 2014;8:111.
112. Frattini F, Pereira Lopes FR, Almeida FM, Rodrigues RF, Boldrini LC, Tomaz
MA, et al. Mesenchymal stem cells in a polycaprolactone conduit promote
sciatic nerve regeneration and sensory neuron survival after nerve injury.
Tissue Eng Part A. 2012;18:2030–9.
113. Carrier-Ruiz A, Evaristo-Mendonça F, Mendez-Otero R, Ribeiro-Resende V.
Biological behavior of mesenchymal stem cells on poly-epsilon-
caprolactone filaments and a strategy for tissue engineering of segments of
the peripheral nerves. Stem Cell Res Ther. 2015;6:128.
114. Ryu H, Oh JE, Rhee KJ, Baik SK, Kim J, Kang SJ, et al. Adipose tissue-derived
mesenchymal stem cells cultured at high density express IFN-β and
suppress the growth of MCF-7 human breast cancer cells. Cancer Lett.
2015;37:213–21.
115. Maltman DJ, Hardy SA, Przyborski SA. Role of mesenchymal stem cells in
neurogenesis and nervous system repair. Neurochem Int. 2011;59:347–56.
116. Kingham PJ, Kolar MK, Novikova LN, Novikov LN, Wiberg M. Stimulating the
neurotrophic and angiogenic properties of human adipose-derived stem
cells enhances nerve repair. Stem Cells Dev. 2014;23:741–54.
117. Bashir J, Sherman A, Lee H, Kaplan L, Hare JM. Mesenchymal stem cell
therapies in the treatment of musculoskeletal diseases. PM R. 2014;6:61–9.
118. Schäfer S, Berger JV, Deumens R, Goursaud S, Hanisch UK, Hermans E.
Influence of intrathecal delivery of bone marrow-derived mesenchymal
stem cells on spinal inflammation and pain hypersensitivity in a rat model
of peripheral nerve injury. J Neuroinflammation. 2014;11:157.
119. Jones J, Estirado A, Redondo C, Pacheco-Torres J, Sirerol-Piquer MS,
Garcia-Verdugo JM, et al. Mesenchymal stem cells improve motor functions
and decrease neurodegeneration in ataxic mice. Mol Ther. 2014;23:130–8.
120. Fargali S, Sadahiro M, Jiang C, Frick AL, Indall T, Cogliani V, et al. Role of
neurotrophins in the development and function of neural circuits that
regulate energy homeostasis. J Mol Neurosci. 2012;48:654–9.
121. McGregor NE, Poulton IJ, Walker EC, Pompolo S, Quinn JMW, Martin TJ,
et al. Ciliary neurotrophic factor inhibits bone formation and plays a
sex-specific role in bone growth and remodeling. Calcif Tissue Int.
2010;86:261–70.
122. Pasquin S, Sharma M, Gauchat JF. Ciliary neurotrophic factor (CNTF):
new facets of an old molecule for treating neurodegenerative and
metabolic syndrome pathologies. Cytokine Growth Factor Rev. 2015.
doi:10.1016/j.cytogfr.2015.07.007.
123. Yu H, Fischer G, Ebert AD, Wu HE, Bai X, Hogan QH. Analgesia for
neuropathic pain by dorsal root ganglion transplantation of
genetically engineered mesenchymal stem cells: initial results. Mol Pain.
2015;11:1–13.
124. Li Y, Guo L, Ahn HS, Kim MH, Kim SW. Amniotic mesenchymal stem cells
display neurovascular tropism and aid in the recovery of injured peripheral
nerves. J Cell Mol Med. 2014;18:1028–34.
125. Teixeira FG, Panchalingam KM, Anjo SI, Manadas B, Pereira R, Sousa N, et al.
Do hypoxia/normoxia culturing conditions change the neuroregulatory
profile of Wharton Jelly mesenchymal stem cell secretome? Stem Cell Res
Ther. 2015;6:133.
126. Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R. Protein
synthesis and secretion in human mesenchymal cells derived from bone
marrow, adipose tissue and Wharton’s jelly. Stem Cell Res Ther. 2014;5:53.
127. Jackson WM, Nesti LJ, Tuan RS. Potential therapeutic applications of muscle-
derived mesenchymal stem and progenitor cells. Expert Opin Biol Ther.
2010;10:505–17.
128. Jackson WM, Aragon AB, Bulken-Hoover JD, Nesti LJ, Tuan RS. Putative
heterotopic ossification progenitor cells derived from traumatized muscle.
J Orthop Res. 2009;27:1645–51.
129. Jackson WM, Lozito TP, Djouad F, Kuhn NZ, Nesti LJ, Tuan RS. Differentiation
and regeneration potential of mesenchymal progenitor cells derived from
traumatized muscle tissue. J Cell Mol Med. 2011;15:2377–88.
130. Jackson WM, Aragon AB, Djouad F, Song Y, Koehler SM, Nesti LJ, et al.
Mesenchymal progenitor cells derived from traumatized human muscle.
J Tissue Eng Regen Med. 2009;3:129–38.
131. Jackson WM, Alexander PG, Bulken-Hoover JD, Vogler JA, Ji Y, McKay P, et al.
Mesenchymal progenitor cells derived from traumatized muscle enhance
neurite growth. J Tissue Eng Regen Med. 2013;7:443–51.
132. Jackson WM, Aragon AB, Onodera J, Koehler SM, Ji Y, Bulken-Hoover JD,
et al. Cytokine expression in muscle following traumatic injury. J Orthop Res.
2011;29:1613–20.
Hofer and Tuan Stem Cell Research & Therapy  (2016) 7:131 Page 13 of 14
133. Kluk MW, Ji Y, Shin EH, Amrani O, Onodera J, Jackson WM, et al.
Fibroregulation of mesenchymal progenitor cells by BMP-4 after traumatic
muscle injury. J Orthop Trauma. 2012;26:693–8.
134. Smith LR. Influencing the secretion of myogenic factors from mesenchymal
stem cells. Stem Cell Res Ther. 2014;5:96.
135. Sohn J, Lu A, Tang Y, Wang B, Huard J. Activation of non-myogenic
mesenchymal stem cells during the disease progression in dystrophic
dystrophin/utrophin knockout mice. Hum Mol Genet. 2015;24:3814–29.
136. Gurgis C, Mokbel N, DiGirolamo DJ. Therapies for musculoskeletal disease:
can we treat two birds with one stone? Curr Osteoporos Rep. 2014;12:142–53.
137. Sassoli C, Nosi D, Tani A, Chellini F, Mazzanti B, Quercioli F, et al. Defining
the role of mesenchymal stromal cells on the regulation of matrix
metalloproteinases in skeletal muscle cells. Exp Cell Res. 2014;323:297–313.
138. Verhoekx JSN, Mudera V, Walbeehm ET, Hovius SER. Adipose-derived stem
cells inhibit the contractile myofibroblast in Dupuytren’s disease.
Plast Reconstr Surg. 2013;132:1139–48.
139. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an
ancient family with structural and functional diversity. Biochim Biophys Acta
Mol Cell Res. 2010;1803:55–71.
140. Seebach E, Holschbach J, Buchta N, Bitsch RG, Kleinschmidt K, Richter W.
Mesenchymal stromal cell implantation for stimulation of long bone healing
aggravates Staphylococcus aureus induced osteomyelitis. Acta Biomater.
2015;21:165–77.
141. Aoyama T, Goto K, Kakinoki R, Ikeguchi R, Ueda M, Kasai Y, et al. An
exploratory clinical trial for idiopathic osteonecrosis of femoral head by
cultured autologous multipotent mesenchymal stromal cells augmented
with vascularized bone grafts. Tissue Eng Part B Rev. 2014;20:233–42.
142. Aoyama T, Fujita Y, Madoba K, Nankaku M, Yamada M, Tomita M, et al.
Rehabilitation program after mesenchymal stromal cell transplantation
augmented by vascularized bone grafts for idiopathic osteonecrosis of the
femoral head: a preliminary study. Arch Phys Med Rehabil. 2015;96:532–9.
143. Vogel S, Börger V, Peters C, Förster M, Liebfried P, Metzger K, et al. Necrotic
cell-derived high mobility group box 1 attracts antigen-presenting cells but
inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem
cells for apoptotic cell death. Cell Death Differ. 2015;22:1219–30.
144. Docheva D, Müller SA, Majewski M, Evans CH. Biologics for tendon repair.
Adv Drug Deliv Rev. 2014;84:222–39.
145. Gaspar D, Holladay C, Pandit A, Zeugolis D. Progress in cell based therapies
for tendon repair. Trends Biotechnol. 2015;84:240–56.
146. Angele P, Kujat R, Koch M, Zellner J. Role of mesenchymal stem cells in
meniscal repair. J Exp Orthop. 2014;1:12.
147. Zellner J, Taeger CD, Schaffer M, Roldan JC, Loibl M, Mueller MB, et al. Are
applied growth factors able to mimic the positive effects of mesenchymal
stem cells on the regeneration of meniscus in the avascular zone?
Biomed Res Int. 2014. doi:10.1155/2014/537686.
148. Ding Z, Huang H. Mesenchymal stem cells in rabbit meniscus and bone
marrow exhibit a similar feature but a heterogeneous multi-differentiation
potential: superiority of meniscus as a cell source for meniscus repair.
BMC Musculoskelet Disord. 2015;16:65.
149. Centeno CJ, Pitts J, Al-sayegh H, Freeman MD. Anterior cruciate ligament
tears treated with percutaneous injection of autologous bone marrow
nucleated cells: a case series. J Pain Res. 2015;8:437–47.
150. Takayama K, Kawakami Y, Mifune Y, Matsumoto T, Tang Y, Cummins JH,
et al. The effect of blocking angiogenesis on anterior cruciate ligament
healing following stem cell transplantation. Biomaterials. 2015;60:9–19.
151. Hogan MV, Walker GN, Cui LR, Fu FH, Huard J. The role of stem cells and
tissue engineering in orthopaedic sports medicine: current evidence and
future directions. Arthrosc J Arthrosc Relat Surg. 2015;31:1017–21.
152. Carvalho ADM, Badial PR, Alvarez LEC, Yamada ALM, Borges AS,
Deffune E, et al. Equine tendonitis therapy using mesenchymal stem cells
and platelet concentrates: a randomized controlled trial. Stem Cell Res Ther.
2013;4:85.
153. Steplewski A, Fertala J, Beredjiklian P, Wang ML, Fertala A. Matrix-specific
anchors: a new concept for targeted delivery and retention of therapeutic
cells. Tissue Eng Part A. 2015;21:1207–16.
154. De Lisio M, Jensen T, Sukiennik RA, Huntsman HD, Boppart M. Substrate and
strain alter the muscle-derived mesenchymal stem cell secretome to
promote myogenesis. Stem Cell Res Ther. 2014;5:74.
155. Meleshko A, Prakharenia I, Kletski S, Isaikina Y. Chimerism of allogeneic
mesenchymal cells in bone marrow, liver, and spleen after mesenchymal
stem cells infusion. Pediatr Transplant. 2013;17:189–94.
156. Lozito TP, Taboas JM, Kuo CK, Tuan RS. Mesenchymal stem cell modification
of endothelial matrix regulates their vascular differentiation. J Cell Biochem.
2009;107:706–13.
157. Lozito TP, Kuo CK, Taboas JM, Tuan RS. Human mesenchymal stem cells
express vascular cell phenotypes upon interaction with endothelial cell
matrix. J Cell Biochem. 2009;107:714–22.
158. Titorencu I, Pruna V, Jinga VV, Simionescu M. Osteoblast ontogeny and
implications for bone pathology: an overview. Cell Tissue Res. 2014;355:23–33.
159. Chen WCW, Péault B, Huard J. Regenerative translation of human
blood-vessel-derived MSC precursors. Stem Cells Int. 2015;2015:11.
160. Pisciotta A, Riccio M, Carnevale G, Lu A, De Biasi S, Gibellini L, et al. Stem
cells isolated from human dental pulp and amniotic fluid improve skeletal
muscle histopathology in mdx/SCID mice. Stem Cell Res Ther. 2015;6:156.
161. Mukherjee P, Mani S. Methodologies to decipher the cell secretome.
Biochim Biophys Acta Proteins Proteomics. 2013;1834:2226–32.
162. Kupcova Skalnikova H. Proteomic techniques for characterisation of
mesenchymal stem cell secretome. Biochimie. 2013;95:2196–211.
163. Caccia D, Dugo M, Callari M, Bongarzone I. Bioinformatics tools for
secretome analysis. Biochim Biophys Acta Proteins Proteomics.
2013;1834:2442–53.
164. Brown KJ, Seol H, Pillai DK, Sankoorikal BJ, Formolo CA, Mac J, et al. The
human secretome atlas initiative: implications in health and disease
conditions. Biochim Biophys Acta Proteins Proteomics. 2013;1834:2454–61.
165. Roberts M, Wall IB, Bingham I, Icely D, Reeve B, Bure K, et al. The global
intellectual property landscape of induced pluripotent stem cell
technologies. Nat Biotechnol. 2014;32:742–8.
166. Sanz-Nogués C, O’Brien T. MSCs isolated from patients with ischemic
vascular disease have normal angiogenic potential. Mol Ther. 2014;22:1888–9.
167. Lin W, Li M, Li Y, Sun X, Li X, Yang F, et al. Bone marrow stromal cells
promote neurite outgrowth of spinal motor neurons by means of
neurotrophic factors in vitro. Neurol Sci. 2014;35:449–57.
168. Lin R-Z, Moreno-Luna R, Li D, Jaminet SC, Greene AK, Melero-Martin JM.
Human endothelial colony-forming cells serve as trophic mediators for
mesenchymal stem cell engraftment via paracrine signaling. Proc Natl Acad
Sci U S A. 2014;111:10137–42.
169. Seebach E, Freischmidt H, Holschbach J, Fellenberg J, Richter W.
Mesenchymal stroma cells trigger early attraction of M1 macrophages and
endothelial cells into fibrin hydrogels, stimulating long bone healing
without long-term engraftment. Acta Biomater. 2014;10:4730–41.
170. Tsai TL, Wang B, Squire MW, Guo LW, Li WJ. Endothelial cells direct human
mesenchymal stem cells for osteo- and chondro-lineage differentiation
through endothelin-1 and AKT signaling. Stem Cell Res Ther. 2015;6:88.
Hofer and Tuan Stem Cell Research & Therapy  (2016) 7:131 Page 14 of 14
